-
公开(公告)号:US20230017373A1
公开(公告)日:2023-01-19
申请号:US17770924
申请日:2020-10-26
摘要: The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.
-
公开(公告)号:US11897910B2
公开(公告)日:2024-02-13
申请号:US17099268
申请日:2020-11-16
发明人: Balaraman Kalyanaraman , Jacek Michal Zielonka , Gang Cheng , Micael J. Hardy , Olivier Ouari , Ming You
IPC分类号: C07F9/54 , A61P35/04 , A61K31/19 , A61K31/7004 , A61K45/06
CPC分类号: C07F9/5456 , A61P35/04 , A61K31/19 , A61K31/7004 , A61K45/06
摘要: The present invention provides mito-honokiol or mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol or mito-magnolol compounds in the treatment of cancer.
-
公开(公告)号:US09956233B2
公开(公告)日:2018-05-01
申请号:US15294083
申请日:2016-10-14
IPC分类号: A61K31/662 , A61K31/44 , A61K31/4425
CPC分类号: A61K31/662 , A61K31/4425
摘要: The present invention provides modified metformin compounds, particularly mito-metformin compounds, and pharmaceutical compositions thereof. Methods of using the compounds to provide neuroprotection and in the treatment and/or prevention of neurodegenerative diseases are also described.
-
4.
公开(公告)号:US20240109925A1
公开(公告)日:2024-04-04
申请号:US18262985
申请日:2022-01-26
IPC分类号: C07F9/54 , A61K31/475 , A61K31/519 , A61P35/00
CPC分类号: C07F9/5442 , A61K31/475 , A61K31/519 , A61P35/00
摘要: In the present invention, the inventors provide substituted the hydroxyl group in hydroxyurea (HU) with a triphenylphosphonium (TPP) cation attached to an alkyl group with different chain lengths, generating a new class of mitochondria-targeted hydroxyurea compounds (Mito-HUs). Elongating the alkyl side chain length increased the hydrophobicity of Mito-HUs, and correlated with increased inhibition of oxidative phosphorylation, and antiproliferative effects in tumor cells.
-
公开(公告)号:US20210070787A1
公开(公告)日:2021-03-11
申请号:US17099268
申请日:2020-11-16
发明人: Balaraman Kalyanaraman , Jacek Michal Zielonka , Gang Cheng , Micael J. Hardy , Olivier Ouari , Ming You
摘要: The present invention provides mito-honokiol or mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol or mito-magnolol compounds in the treatment of cancer.
-
公开(公告)号:US11612610B2
公开(公告)日:2023-03-28
申请号:US17397672
申请日:2021-08-09
发明人: Balaraman Kalyanaraman , Jacek Michal Zielonka , Gang Cheng , Micael Joël Hardy , Olivier Ouari
摘要: The present invention provides mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-magnolol compounds in the treatment of cancer, especially anti-cancer therapy or kinase resistant cancers.
-
公开(公告)号:US11352382B2
公开(公告)日:2022-06-07
申请号:US16959975
申请日:2019-01-03
IPC分类号: C07F9/6503 , A61P35/04 , C07F9/6558
摘要: The present invention relates to mito-lonidamine compounds, compositions and methods of use in the treatment of cancer.
-
公开(公告)号:US20210395280A1
公开(公告)日:2021-12-23
申请号:US17289646
申请日:2019-11-01
摘要: The present invention provides novel mito-pyridinium compounds, prodrugs and the uses thereof for the treatment of cancer, particularly drug resistant cancer.
-
公开(公告)号:US11083739B2
公开(公告)日:2021-08-10
申请号:US16714461
申请日:2019-12-13
发明人: Balaraman Kalyanaraman , Jacek Michal Zielonka , Gang Cheng , Micael Joël Hardy , Olivier Ouari
摘要: The present invention provides mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-magnolol compounds in the treatment of cancer, especially anti-cancer therapy or kinase resistant cancers.
-
公开(公告)号:US10576093B2
公开(公告)日:2020-03-03
申请号:US15963648
申请日:2018-04-26
IPC分类号: A61K31/662 , A61K31/44 , A61K31/4425
摘要: The present invention provides modified metformin compounds, particularly mito-metformin compounds, and pharmaceutical compositions thereof. Methods of using the compounds to provide neuroprotection and in the treatment and/or prevention of neurodegenerative diseases are also described.
-
-
-
-
-
-
-
-
-